Home » Stocks » ANGN

Angion Biomedica Corp. (ANGN)

Stock Price: $16.05 USD -1.07 (-6.25%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $16.25 +0.20 (1.25%) Mar 5, 5:28 PM
Market Cap 498.08M
Revenue (ttm) 3.12M
Net Income (ttm) -67.25M
Shares Out 28.78M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $16.05
Previous Close $17.12
Change ($) -1.07
Change (%) -6.25%
Day's Open 17.44
Day's Range 12.56 - 17.99
Day's Volume 324,505
52-Week Range 12.56 - 26.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

GlobeNewsWire - 3 weeks ago

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercializ...

GlobeNewsWire - 1 month ago

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercializa...

NASDAQ - 1 month ago

Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The com...

SEC - 1 month ago

Angion Biomedica Corp. has filed to go public with an IPO on the NASDAQ.

About ANGN

Angion Biomedica is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our pipeline of product candidates has been developed internally and is the result of over 20 years of in-house research by a team that has made seminal contributions to the understanding of HGF and fibrotic pathways. Our lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that we are currently evaluating in mul... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Feb 5, 2021
CEO
Jay R. Venkatesan, M.D.
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
ANGN
Full Company Profile

Financial Performance

In 2019, ANGN's revenue was $1.49 million, a decrease of -63.09% compared to the previous year's $4.03 million. Losses were -$40.66 million, 103.0% more than in 2018.

Financial Statements